Advisor Consultant Network Inc. acquired a new position in shares of Sanofi (NYSE:SNY) during the third quarter, Holdings Channel reports. The fund acquired 224,375 shares of the company’s stock, valued at approximately $8,568,000. Sanofi accounts for 1.2% of Advisor Consultant Network Inc.’s holdings, making the stock its 24th largest position.

Other large investors have also made changes to their positions in the company. Boston Partners boosted its stake in shares of Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock worth $309,774,000 after buying an additional 7,330,168 shares during the period. Dodge & Cox boosted its stake in shares of Sanofi by 3.0% in the second quarter. Dodge & Cox now owns 55,155,913 shares of the company’s stock valued at $2,308,275,000 after buying an additional 1,625,784 shares during the last quarter. Hamlin Capital Management LLC purchased a new stake in shares of Sanofi during the second quarter valued at $56,725,000. Hotchkis & Wiley Capital Management LLC boosted its stake in shares of Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock valued at $478,434,000 after buying an additional 1,267,118 shares during the last quarter. Finally, Senzar Asset Management LLC purchased a new stake in shares of Sanofi during the second quarter valued at $46,173,000. 9.80% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) traded down 0.5527% on Wednesday, hitting $40.2165. 774,722 shares of the company traded hands. The firm’s 50-day moving average is $39.23 and its 200 day moving average is $39.82. Sanofi has a 1-year low of $36.81 and a 1-year high of $44.63. The firm has a market capitalization of $103.52 billion, a P/E ratio of 23.3207 and a beta of 0.97.

COPYRIGHT VIOLATION NOTICE: This piece was reported by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at http://www.dailypolitical.com/2016/11/30/advisor-consultant-network-inc-purchases-new-stake-in-sanofi-sny.html.

Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, October 27th. Leerink Swann reissued a “buy” rating on shares of Sanofi in a research report on Monday, September 26th. Goldman Sachs Group Inc. assumed coverage on shares of Sanofi in a research report on Monday, November 7th. They set a “neutral” rating for the company. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating in a research report on Tuesday. Finally, Jefferies Group reissued a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $60.50.

About Sanofi

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.